CRISPR Therapeutics (CRSP) Competitors $66.06 -2.08 (-3.05%) Closing price 04:00 PM EasternExtended Trading$66.22 +0.16 (+0.25%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRSP vs. ALLO, AXSM, BEAM, EDIT, KALA, MRNA, NTLA, VRTX, SMMT, and INSMShould you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Allogene Therapeutics (ALLO), Axsome Therapeutics (AXSM), Beam Therapeutics (BEAM), Editas Medicine (EDIT), KALA BIO (KALA), Moderna (MRNA), Intellia Therapeutics (NTLA), Vertex Pharmaceuticals (VRTX), Summit Therapeutics (SMMT), and Insmed (INSM). These companies are all part of the "medical" sector. CRISPR Therapeutics vs. Its Competitors Allogene Therapeutics Axsome Therapeutics Beam Therapeutics Editas Medicine KALA BIO Moderna Intellia Therapeutics Vertex Pharmaceuticals Summit Therapeutics Insmed CRISPR Therapeutics (NASDAQ:CRSP) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment. Does the media refer more to CRSP or ALLO? In the previous week, CRISPR Therapeutics had 22 more articles in the media than Allogene Therapeutics. MarketBeat recorded 24 mentions for CRISPR Therapeutics and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.78 beat CRISPR Therapeutics' score of 0.46 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CRSP or ALLO more profitable? Allogene Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,023.64%. CRISPR Therapeutics' return on equity of -20.08% beat Allogene Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CRISPR Therapeutics-1,023.64% -20.08% -17.13% Allogene Therapeutics N/A -52.98%-41.28% Which has stronger earnings and valuation, CRSP or ALLO? Allogene Therapeutics has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCRISPR Therapeutics$37.31M152.91-$366.25M-$4.52-14.62Allogene Therapeutics$20K16,514.12-$257.59M-$1.23-1.23 Which has more volatility and risk, CRSP or ALLO? CRISPR Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Do analysts recommend CRSP or ALLO? CRISPR Therapeutics presently has a consensus price target of $71.31, suggesting a potential upside of 7.95%. Allogene Therapeutics has a consensus price target of $8.44, suggesting a potential upside of 459.23%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CRISPR Therapeutics 1 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.53Allogene Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Do insiders & institutionals have more ownership in CRSP or ALLO? 69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 4.3% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryAllogene Therapeutics beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks. Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRSP vs. The Competition Export to ExcelMetricCRISPR TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.88B$3.06B$5.70B$9.48BDividend YieldN/A2.37%4.59%3.99%P/E Ratio-14.6220.7327.9019.95Price / Sales152.91321.12442.19102.72Price / CashN/A43.2336.5558.97Price / Book2.928.308.635.90Net Income-$366.25M-$55.19M$3.24B$258.42M7 Day Performance19.91%5.07%3.22%1.94%1 Month Performance41.21%17.61%10.72%12.02%1 Year Performance19.26%7.03%34.94%20.81% CRISPR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRSPCRISPR Therapeutics1.7589 of 5 stars$66.06-3.1%$71.31+8.0%+19.1%$5.88B$37.31M-14.62460Analyst ForecastAnalyst RevisionALLOAllogene Therapeutics3.3909 of 5 stars$1.35+7.6%$8.44+527.8%-46.1%$294.19M$20K-1.09310AXSMAxsome Therapeutics4.7148 of 5 stars$109.71-1.8%$172.33+57.1%+24.2%$5.42B$385.69M-19.09380Analyst RevisionBEAMBeam Therapeutics2.317 of 5 stars$21.17+2.0%$48.75+130.2%-26.9%$2.13B$63.52M-4.59510Analyst UpgradeAnalyst RevisionEDITEditas Medicine4.0444 of 5 stars$3.15+14.0%$4.70+49.4%-38.3%$261.59M$32.31M-1.03230High Trading VolumeKALAKALA BIO3.7838 of 5 stars$5.85+1.8%$13.00+122.4%-20.2%$37.38M$3.89M-0.7030MRNAModerna4.2445 of 5 stars$31.34+0.2%$46.61+48.7%-71.4%$12.14B$3.24B-3.605,800Analyst ForecastNTLAIntellia Therapeutics4.5653 of 5 stars$12.71+5.4%$33.37+162.5%-46.2%$1.31B$57.88M-2.41600Analyst RevisionVRTXVertex Pharmaceuticals4.3022 of 5 stars$459.47-0.1%$511.71+11.4%-2.7%$117.97B$11.02B-117.196,100Positive NewsSMMTSummit Therapeutics3.2163 of 5 stars$26.32+0.5%$34.67+31.7%+177.6%$19.58B$700K-77.55110INSMInsmed4.0666 of 5 stars$102.47-0.1%$108.47+5.9%+36.1%$19.40B$363.71M-17.191,271Positive NewsAnalyst ForecastInsider Trade Related Companies and Tools Related Companies Allogene Therapeutics Alternatives Axsome Therapeutics Alternatives Beam Therapeutics Alternatives Editas Medicine Alternatives KALA BIO Alternatives Moderna Alternatives Intellia Therapeutics Alternatives Vertex Pharmaceuticals Alternatives Summit Therapeutics Alternatives Insmed Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRSP) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRSP Stock Alerts